Pall Corporation (PLL) is a supplier of filtration, separation and purification technologies, principally made by the company, for the removal of solid, liquid and gaseous contaminants from a range of liquids and gases. The company serves customers through two businesses globally: Life Sciences and Industrial. While Pall competes with many companies in the Life Sciences markets and Industrial, few companies operate in both, like ESCO Technologies Inc. (ESE) and Danaher Corp. (DHR).
In this article, let's take a look at this company and try to explain to investors the reasons this is an apparently appealing investment.
Cost Reduction
Pall targeted $100 million in structural cost reductions over the next three years. It saved $50 million during fiscal 2013 by reducing SG&A expenses along with other costs. It expects to save another $50 million in the next couple of years. Further, we think new management is going to focus on improving the company's cost structure in emerging markets as well. Moreover, Pall will focus on markets such as Asia, expanding its outsourcing network in low-cost countries.
Top Diversified Bank Stocks To Watch Right Now: General Mills Inc (GIS)
General Mills, Inc. (General Mills), incorporated on June 20, 1928, is a manufacturer and marketer of branded consumer foods sold through retail stores. The Company is also a supplier of branded and unbranded food products to the foodservice and commercial baking industries. The Company manufactures its products in 15 countries and markets them in more than 100 countries. The Company's joint ventures manufacture and market products in more than 130 countries and republics worldwide. General Mills operates in three segments: U.S. Retail, International, and Bakeries and Foodservice. In addition, the Company sells ready-to-eat cereals through its Cereal Partners Worldwide (CPW) joint venture. In February 2012, General Mills acquired Food Should Taste Good, a natural snack foods company based in Needham Heights, Mass. During the fiscal year ended May 27, 2012, the Company acquired a 51% interest in Yoplait S.A.S. and a 50% interest in Yoplait Marques S.A.S. In August 2012, it acquired Yoki Alimentos SA.
General Mills�� ready-to-eat cereals consists of Cheerios, Wheaties, Lucky Charms, Total, Trix, Golden Grahams, Chex, Kix, Fiber One, Reese�� Puffs, Cocoa Puffs, Cookie Crisp, Cinnamon Toast Crunch, Clusters, Oatmeal Crisp and Basic 4. Its refrigerated yogurt include Yoplait, Trix, Delights, Go-GURT, Fiber One, YoPlus, Whips!, Mountain High, Liberte, YOP, Perle de Lait, Petits Filous and Panier. The Company�� refrigerated and frozen dough products consists of Pillsbury, the Pillsbury Doughboy character, Grands!, Golden Layers, Big Deluxe, Toaster Strudel, Toaster Scrambles, Simply, Savorings, Jus-Rol, Latina, Pasta Master, Wanchai Ferry, V.Pearl and La Saltena. The dry dinners and shelf stable and frozen vegetable products includes Betty Crocker, Hamburger Helper, Tuna Helper, Chicken Helper, Old El Paso, Green Giant, Potato Buds, Suddenly Salad, Bac*O��, Betty Crocker Complete Meals, Valley Selections, Simply Steam, Valley Fresh Steamers, Wanchai Ferry, Diablitos and Parampara. Its gr! ain, fruit, and savory snacks consists of Nature Valley, Fiber One, Betty Crocker, Fruit Roll-Ups, Fruit By The Foot, Gushers, Chex Mix, Gardetto��, Bugles, Food Should Taste Good and Larabar. The sessert and baking mixes includes Betty Crocker, SuperMoist, Warm Delights, Bisquick and Gold Medal. Ready-to-serve soup consists of Progresso. The Company�� ice cream and frozen desserts include Haagen-Dazs, Secret Sensations, Cream Crisp and Dolce. Its frozen pizza and pizza snacks includes Totino��, Jeno��, Pizza Rolls, Party Pizza, Pillsbury Pizza Pops and Pillsbury Pizza Minis. General Mills�� organic products include Cascadian Farm and Muir Glen.
The Company�� products are marketed under trademarks and service marks that are owned by or licensed to the Company. Some of the brand names include Dora the Explorer, Disney Cars, and Disney Princesses for yogurt, and Dora the Explorer for cereal; Reese's Puffs for cereal; Hershey's chocolate for a variety of products; Weight Watchers as an endorsement for soup and frozen vegetable products; Macaroni Grill for dry and frozen dinners; Sunkist for baking products and fruit snacks; Cinnabon for refrigerated dough, frozen pastries, and baking products; Bailey's for super-premium ice cream, and a range of characters and brands for fruit snacks, including Scooby Doo, Batman, Tom and Jerry, Ocean Spray, Thomas the Tank Engine, My Little Pony, Transformers, and various Warner Bros. and Nickelodeon characters. Its primary customers include grocery stores, mass merchandisers, membership stores, natural food chains, drug, dollar and discount chains, commercial and noncommercial foodservice distributors and operators, restaurants, and convenience stores.
U.S. Retail segment
The Company�� U.S. Retail segment reflects business with a range of grocery stores, mass merchandisers, membership stores, natural food chains, and drug, dollar and discount chains operating throughout the United States. Its product categories in thi! s busines! s segment include ready-to-eat cereals, refrigerated yogurt, ready-to-serve soup, dry dinners, shelf stable and frozen vegetables, refrigerated and frozen dough products, dessert and baking mixes, frozen pizza and pizza snacks, grain, fruit and savory snacks, and a range of organic products, including granola bars, cereal and soup.
International segment
The Company�� International segment consists of retail and foodservice businesses outside of the United States. In Canada, its product categories include ready-to-eat cereals, shelf stable and frozen vegetables, dry dinners, refrigerated and frozen dough products, dessert and baking mixes, frozen pizza snacks, refrigerated yogurt, and grain and fruit snacks. In markets outside North America, its product categories include super-premium ice cream and frozen desserts, refrigerated yogurt, grain snacks, shelf stable and frozen vegetables, refrigerated and frozen dough products, and dry dinners. Its International segment also includes products manufactured in the United States for export, mainly to Caribbean and Latin American markets, as well as products it manufactures for sale to its international joint ventures.
Bakeries and Foodservice segment
In Company�� Bakeries and Foodservice segment its product categories include cereals, snacks, refrigerated yogurt, unbaked and fully baked frozen dough products, baking mixes, and flour. It sells to distributors and operators in many customer channels, including foodservice, convenience stores, vending and supermarket bakeries.
Advisors' Opinion:- [By Travis Hoium]
General Mills (NYSE: GIS ) just reported fiscal fourth-quarter earnings that matched Wall Street's expectations. Revenue rose 8% in the quarter to $4.4 billion on an 11% volume increase, and earnings of $0.53 were in line with analyst estimates. For the full year, earnings of $2.69 per share were at the high end of the company's expectations. U.S. growth was pretty anemic, coming in at just 1% for the full year. But General Mills has been able to grow 24% internationally in fiscal 2013, and that has helped drive results. �
- [By Maxx Chatsko]
Major food producers General Mills (NYSE: GIS ) and Kroger (NYSE: KR ) are taking action. Aside from funding the University of Chicago's research, General Mills offers 300 products in popular brands such as Progresso soups, Betty Crocker, and Pillsbury that have kicked wheat-sourced ingredients off their label. In fact, the company's Rice Chex was the first major cereal in the United States to go gluten-free.
5 Best Life Sciences Stocks To Buy For 2014: STARWOOD PROPERTY TRUST INC.(STWD)
Starwood Property Trust, Inc., a real estate investment trust, primarily focuses on originating, investing in, financing, and managing commercial mortgage loans and other commercial real estate debt investments, commercial mortgage-backed securities, and other commercial real estate-related debt investments. It also focuses to invest in commercial properties subject to net leases, residential mortgage loans, and residential mortgage-backed securities. SPT Management, LLC serves as the manager of Starwood Property Trust, Inc. The company qualifies as a real estate investment trust for federal income tax purposes and would not be subject to federal corporate income taxes, if it distributes at least 90% of its taxable income to its stockholders. Starwood Property Trust was founded in 2009 and is headquartered in Greenwich, Connecticut.
Advisors' Opinion:- [By Amanda Alix]
Other companies are currently mulling single-family REIT IPOs, too. Colony recently announced�that it plans to spin off its Colony American Homes, which owns over 9,500 homes with average monthly rents of $1,277. Barry Sternlicht, CEO of commercial mortgage investment REIT Starwood Property Trust (NYSE: STWD ) has also said that he is seriously considering�spinning off his company's real estate holdings into a single-family REIT within the next few months.
5 Best Life Sciences Stocks To Buy For 2014: Cell Therapeutics Inc (CTIC)
Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.
Pixuvri
As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.
OPAXIO
OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.
Tosedostat
In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.
Brostallicin
As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).
The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.
Advisors' Opinion:- [By Nathalie Tadena]
Among the companies with shares expected to actively trade in Friday’s session are Vanda Pharmaceuticals Inc.(VNDA), Kimberly-Clark(KMB) and Cell Therapeutics(CTIC).
- [By MONEYMORNING]
Cell Therapeutics Inc. (Nasdaq: CTIC), based in Seattle, Wash., acquires, develops, and commercializes treatments for cancers, including non-Hodgkin's leukemia and ovarian, neck, and brain cancers. The company just announced it has completed patient enrollment in clinical trials for an investigational agent to be used as a maintenance therapy in ovarian cancer patients. The trial is being conducted by the Gynecologic Oncology Group, one of the National Cancer Institute's funded research groups. Roth Capital recently reiterated a "Buy" rating on the stock and raised its price target from $6 to $7. Roth believes the company's treatment for leukemia, Pacritinib, is effectively evolving. Additionally, the investment firm sees potential in CTIC's Tosedostat, which deprives tumor cells of the amino acid building blocks needed to make proteins necessary for tumor cell survival. Shares rose 2% Tuesday to $3.52 on volume of 6 million shares.
5 Best Life Sciences Stocks To Buy For 2014: Skilled Healthcare Group Inc.(SKH)
Skilled Healthcare Group, Inc., through its subsidiaries, operates skilled nursing facilities, assisted living facilities, hospices, home health providers, and a rehabilitation therapy business. Its skilled nursing facilities provide specialty care, such as chemotherapy, enteral/parenteral nutrition, tracheotomy care, and ventilator care, as well as offers various services, including room and board, special nutritional programs, social services, recreational activities, and related healthcare and other services. These skilled nursing facilities include Express Recovery, a unit that provides skilled nursing care and rehabilitation therapy for patients recovering from conditions, such as joint replacement surgery, and cardiac and respiratory ailments. The company?s assisted living facilities provide residential accommodations, activities, meals, security, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support , but not the level of nursing care provided in a skilled nursing facility. Skilled Healthcare Group also offers ancillary services, such as physical, occupational, and speech therapy, as well as rehabilitation therapy service to third-party skilled nursing operators. In addition, the company offers hospice services comprising palliative and clinical care, education, and counseling with a focus on the physical, spiritual, and psychosocial needs of terminally ill individuals and their families. As of December 31, 2010, it owned or leased 78 skilled nursing facilities and 22 assisted living facilities, together comprising 10,830 licensed beds in California, Texas, Iowa, Kansas, Missouri, Nevada, and New Mexico. The company has a joint venture with APS?Summit Care Pharmacy, LLC that operates a pharmacy in Austin, Texas. Skilled Healthcare Group, Inc. is based in Foothill Ranch, California.
Advisors' Opinion:- [By Rich Smith]
Foothill Ranch, Calif.-based Skilled Healthcare (NYSE: SKH ) needs a new CEO.
On Monday, the assisted living facilities operator announced that Chief Executive Officer Boyd Hendrickson plans to retire from the company at the end of this year. A search for a replacement is now under way.
No comments:
Post a Comment